Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Belgische aandelen   /   Eckert-Ziegler

Belgische aandelen« Terug naar discussie overzicht

Eckert-Ziegler

Volgen
77 Posts
Pagina: «« 1 2 3 4 | Laatste | Omlaag ↓
  10. forum rang 4 Nel 5 november 2013 08:41
    Seneffe, Belgium, November 4, 2013, Eckert & Ziegler BEBIG announces to have received an order for the delivery of their state-of-the art MultiSource® afterloaders for HDR brachytherapy representing one of the largest single orders ever received by the company. The decision in favour of MultiSource® was driven by the systems unique miniaturized cobalt-60 source as well as exclusive safety features enabling for a high level of accuracy. "Due to its technical characteristics and the long half-life of the isotope used, our afterloader is ideal for the region. The radiation source only needs to be replaced every five years," said Abel Luzuriaga, Managing Director of Eckert & Ziegler BEBIG. A part of the ordered devices will already be delivered within the next month while the remaining afterloaders are expected in Bangladesh in the first quarter of 2014. The deal has a total value of around 3.1 million € and is a positive result of our increased sales activities in that region. "We are pleased to see that emerging countries in Asia, Africa and South America are increasingly gaining access to the latest medical infrastructure that has long been available in other parts of the world. Our range of MultiSource® devices with their distinguished characteristics is exactly what decision-makers are looking for," Abel Luzuriaga added. The tender was advertised in the context of the "Health, Population & Nutrition Sector Development Program (HPNSDP)". Amongst others, the five year program aims to enhance the cancer treatment in The People's Republic of Bangladesh that is facing rising incidences of the disease. It is the third sector-wide program of its kind in the country. Supported by the European Union, the World Bank, UNICEF, the World Health Organization (WHO) and 17 more development partners, the program will end in June 2016. - See more at: www.beursig.nl/forum/viewtopic.php?f=...
  12. forum rang 4 Nel 19 december 2013 14:21
    Eckert & Ziegler BEBIG announces the manufacturing and distribution of its globally respected Low Dose Rate Brachytherapy Products in the U.S. Seneffe - Belgium, December 9, 2013. Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB) is pleased to announce that it is resuming production and distribution in its recently acquired manufacturing facility in Oxford, Connecticut (USA). Following delivery of individual products in the past few weeks, the full LDR brachytherapy portfolio, which includes the innovative core products AnchorSeed® and VariStrand(TM), is now once again available to American customers."Taking up production again at our new manufacturing facility in Connecticut marks a milestone in our company's history. We are pleased to announce that the remediation work has been completed successfully so we can once again supply our valued brachytherapy products 'Made in the USA' to the American market in the usual way," explained Dr. Edgar Löffler, Managing Director of Eckert & Ziegler BEBIG.Eckert & Ziegler BEBIG took over the business unit in Oxford from Biocompatibles with effect November 1, 2013. Biocompatibles had voluntarily suspended manufacture and delivery of its products in May 2013 after a warning letter from the FDA claiming shortcomings in its documentation of the manufacturing process.About Eckert & Ziegler BEBIG Contributing to saving lives!Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with subsidiaries throughout Europe, in the USA, India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.

    Eckert & Ziegler Bebig neemt een pionier in brachytherapie over, het Amerikaanse bedrijf Mick Radio Nuclear Instruments (MRNI). Een overnameprijs is niet bekendgemaakt. MRNI tekende in het boekjaar 2012/2013 voor een omzet van omgerekend 4 miljoen euro. MRNI is een van de leidinggevende bedrijven in de ontwikkeling van applicatoren voor brachytherapie. Daarbij worden kankertumoren bestraald door middel van radioactieve implantaten. MRNI werd in 1972 opgericht en is gevestigd in Mount Vernon, New York. Met de overname van MRNI zet Eckert & Ziegler Bebig zijn expansie in de Verenigde Staten verder. Eerder kondigde de groep al aan de brachytherapie-activiteiten van Biocompatibles over te nemen. - See more at: beursig.nl/forum/viewtopic.php?f=4&am...
  17. forum rang 4 Nel 27 maart 2014 09:04
    Overall market development of our core business continues to be positive, and Eckert & Ziegler BEBIG’s order bookings grew by 10% compared to last year.

    sale ging om deze reden omlaag

    Overall, revenues were lower than in 2012, as our ongoing core business was unable to recover from the impact of last year’s ZAO MSM-Medimpex agreement and from the changes of eliminating a part of our unprofitable merchandise business in France.

    ev er aandeel weer gestegen naar 2,64
    gaat een mooi jaar worden deals die komen gaan.
    www.bebig.eu/fileadmin/ibt-bebig.eu/f...
77 Posts
Pagina: «« 1 2 3 4 | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
Air France-KLM 8,020 +0,32 +4,18%
HEIJMANS KON 31,550 +1,20 +3,95%
ASML 706,700 +24,20 +3,55%
Aperam 27,120 +0,88 +3,35%
UMG 27,030 +0,84 +3,21%
ADYEN NV 1.563,000 +47,00 +3,10%
ASMI 547,000 +15,80 +2,97%
SHELL PLC 32,005 +0,91 +2,91%
ALLFUNDS GROUP 5,110 +0,14 +2,82%
Alfen N.V. 14,465 +0,39 +2,73%
FASTNED 21,050 +0,55 +2,68%
PostNL 0,985 +0,02 +2,55%
OCI 11,380 +0,28 +2,52%
Philips Koninklijke 26,860 +0,65 +2,48%
Arcadis 55,350 +1,20 +2,22%
Kendrion 10,400 +0,22 +2,16%
Brunel 9,470 +0,20 +2,16%
Fugro 15,450 +0,32 +2,12%
Nedap N.V. 59,600 +1,20 +2,05%
ArcelorMittal 24,270 +0,48 +2,02%
CTP 16,180 +0,30 +1,89%
EXOR NV 91,550 +1,60 +1,78%
Sif Holding 11,960 +0,20 +1,70%
AEX 919,00 +14,06 +1,55%
TKH 35,360 +0,54 +1,55%
RELX 48,080 +0,72 +1,52%
ACOMO 18,100 +0,26 +1,46%
NSI 21,450 +0,30 +1,42%
Eurocommercial Properties 23,300 +0,30 +1,30%
ASCX 1.266,31 +14,75 +1,18%
WDP 20,680 +0,24 +1,17%
Pharming 0,865 +0,01 +1,17%
Wereldhave 14,540 +0,16 +1,11%
AMX 844,19 +8,87 +1,06%
Wolters Kluwer 175,050 +1,70 +0,98%
Corbion 23,020 +0,22 +0,96%
UNILEVER PLC 55,720 +0,50 +0,91%
Fagron 19,160 +0,16 +0,84%
AALBERTS NV 34,400 +0,26 +0,76%
B&S Group SA 4,200 +0,03 +0,72%
NX FILTRATION 2,900 +0,02 +0,69%
IMCD 151,100 +0,90 +0,60%
Flow Traders 23,720 +0,14 +0,59%
BAM 4,114 +0,02 +0,54%
PROSUS 36,655 +0,20 +0,53%
CM.COM 5,790 +0,03 +0,52%
Heineken 67,520 +0,34 +0,51%
Basic-Fit 24,480 +0,12 +0,49%
BESI 122,900 +0,60 +0,49%
JDE PEET'S 16,840 +0,08 +0,48%
JUST EAT TAKEAWAY 11,760 +0,05 +0,47%
Ahold Delhaize 34,380 +0,16 +0,47%
Van Lanschot Kempen NV 47,500 +0,20 +0,42%
RENEWI 9,580 +0,04 +0,42%
Sligro 10,720 +0,04 +0,37%
Vopak 43,180 +0,16 +0,37%
ABN AMRO BANK N.V. 16,365 +0,05 +0,31%
ForFarmers 3,360 +0,01 +0,30%
Accsys 0,550 +0,00 +0,18%
Avantium 1,736 +0,00 +0,12%
ING 16,150 +0,01 +0,07%
INPOST 15,860 0,00 0,00%
TomTom 5,220 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
KPN 3,554 -0,07 -1,88%
DSM FIRMENICH AG 98,380 -1,42 -1,42%
VASTNED 28,400 -0,40 -1,39%
RANDSTAD NV 41,740 -0,53 -1,25%
THEON INTERNAT 13,300 -0,16 -1,19%
Akzo Nobel 56,340 -0,58 -1,02%
Aegon 6,316 -0,06 -0,88%
ASR Nederland 47,700 -0,34 -0,71%
AZERION 1,590 -0,01 -0,63%
SBM Offshore 17,690 -0,10 -0,56%
EBUSCO HOLDING 0,917 0,00 -0,52%
SIGNIFY NV 21,100 -0,08 -0,38%
NN Group 44,260 -0,15 -0,34%
AMG Critical Materials N.V. 13,960 -0,03 -0,21%
Galapagos 22,180 -0,04 -0,18%
vlag naam koers verschil relatief verschil
AEX 919,00 +14,06 +1,55%
AEX GR 3.604,61 +55,14 +1,55%
Germany40^ 21.728,30 +1,10 +0,01%
FTSE 100 8.646,88 +89,07 +1,04%
Europe50^ 5.285,91 +3,70 +0,07%
US30^ 44.885,30 0,00 0,00%
Nasd100^ 21.508,10 0,00 0,00%
US500^ 6.070,73 0,00 0,00%
Japan225^ 39.582,10 0,00 0,00%
VD-NEW 14,74 -0,80 -5,14%
#/^ Index indications calculated real time, zie disclaimer